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ABSTRACT
Objective: To evaluate levofloxacin efficiency for treatment of chronic suppurative otitis media in sample of Iraqi patients.
Methods: This is a prospective study which includes 50 patients of different age groups diagnosed with CSOM. Aural toilet and otosporin ear drop 
performed in clinic, then levofloxacin prescribed as single oral tablet daily for 4-6 weeks. Patients were examined every 2 weeks for 8 weeks and then 
once by month for 6 months to evaluate the efficiency of treatment.
Results: Forty patients (80%) showed complete dryness and healing. Discharge decreased upon the visits with more dryness observed after 4 weeks 
of treatment. Signs of healing and tympanic perforation closure apparently occur about 1 month from the initial treatment in 32 patients (80% of 
successful treatment). Culture sensitivity tests results were Pseudomonas aeruginosa and Klebsiella species in discharge materials.
Conclusion: Levofloxacin is a safe and effective drug for the treatment of CSOM and promising treatment for CSOM in combination with aural toilet. 
The main species of microorganism detected were P. aeruginosa and Klebsiella.
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INTRODUCTION
Chronic suppurative otitis media (CSOM) is a chronic inflammation 
of the middle ear and mastoid cavity, with recurrent ear discharges 
(otorrhea) and tympanic perforation [1]. Tympanic perforations with 
a discharge for periods from 6 weeks to 3 months, despite medical 
treatment, were diagnosed as CSOM [2].
The infection may occur during childhood, with a peak around 2 years 
started as acute otitis media [3]. Upper respiratory infection, which 
is common during childhood, poor socioeconomic status, and poor 
hygiene and nutrition, maybe accounts for CSOM development [4]. This 
may explain the high prevalence of CSOM in the developing countries. 
In addition, gene abnormalities have implicated as host risk factors for 
CSOM [5]. Mild-to-moderate hearing impairment among children and 
young people, meningitis, and brain abscess are some complications of 
CSOM that impair patients’ hearing and potentially fatal [6].
Pathogenesis of CSOM is complex and multifactorial. In adequate 
treatment of middle ear infection may cause epithelial migration over 
the edges of perforation , in addition to other factors like immunological 
and genetic factors Eustachian tube morphology, and types of bacterial 
isolate and biofilm formation play a role in CSOM pathogenesis [7,8].
Treatment of CSOM aimed to improve symptoms, heal perforations, and 
reduce complications, with minimum adverse effects. various types of 
treatment protocol used like: topical antibiotics plus corticosteroids, oral 
antibiotics plus topical antiseptics or systemic antibiotic alone [9,10]. 
Ear cleansing and surgical treatment may be a choice of treatment 
in certain cases[11]. Isolates of bacteria determine the use of proper 
antibiotics. Since the commonly isolates are Pseudomonas aeruginosa 
and Staphylococcus aureus [12], fluoroquinolones such as ciprofloxacin 
and levofloxacin show greater potency against Pseudomonas species 
according to Ikeda et al. [13]. levofloxacin is one of fluoroquinolone 
broad spectrum antibiotics, that is well absorbed, widely distributed 
through body tissue with long period of  action  that allow single 
dosing. In addition to that levofloxacin  is available for intravenous and 
oral routs [13,14]. It acts by blocking bacterial DNA synthesis through 
inhibition of bacterial topoisomerase II [14]. Common adverse effects 
are nausea, vomiting, diarrhea, and gastric upset. Levofloxacin is one 
of the respiratory fluoroquinolones which is active against upper and 
lower respiratory tract infections. According to the previous facts, 
the purpose of the present study is to evaluate the efficiency of oral 
levofloxacin in CSOM treatment in a sample of Iraqi patients.
METHODS
This is a prospective study conducted between September 2015 and 
December 2016 including patients referred to a consultant, Auto 
Laryngeal Clinic in Al-Hilla General Teaching Hospital.
Fifty patients of different age groups were included (Table 1). 80% of 
patients were rural and 20% urban with failed treatment history. All 
patients had chronic mastoiditis and 100% conductive hearing loss 
between 40 and 70 dB. Older aged patients already have sensory neural 
hearing loss in addition to conductive hearing loss (Table 2).
Inclusion criteria
Patients with CSOM signs and symptoms including offensive ear 
discharge and tympanic eardrum perforation with more than 6-week 
history were included in the study.
Exclusion criteria
Patients with CSOM symptoms less than 6 weeks history and/or 
patients with discharge without perforation or perforation without 
discharge were excluded.
Diagnosis
All patients were clinically examined by tympanoscope, and diagnosis 
of CSOM was confirmed by computerized tomography which reveals 
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sclerosis mastoid air cells, granulomatous tissue, polyps, and erosion 
ossicles. culture sensitivity test performed to identify micro organism 
species involved.
Study design
After confirmed diagnosis, patients with COSM treated as follows.
Local aural toilet by either electrical suction or using cotton wool swabs 
with iodine 4% for cleaning was performed and then otosporin drops 
applied topically in the clinic and each visit; after that, levofloxacin 
was prescribed as a single oral daily dose for 4-6 weeks. Patients were 
examined every 2 weeks for 8 weeks and then once by month for 
6 months to evaluate the efficiency of treatment. Patients who develop 
adverse effect during the treatment period of 6 weeks were asked to 
stop medical treatment for 1 week and then start again as a single oral 
daily dose for the rest of the treatment period.
Culture sensitivity test was made in accordance with the standard 
laboratory procedures depending on minimum inhibitory zone 
diameters.
Drugs
Levofloxacin tablets of 500 mg strength (Sanofi-Aventis,France).
Ethical statement
The study protocol was reviewed and approved by the Institutional 
Review Board of Al-Hilla Teaching Hospital and Ethical Board of 
Medical College of Babylon University. Written informed consent from 
patients was obtained.
RESULTS
At the end of the study period from 50 treated patients, 40 patients 
show complete dryness and healing as expressed in Table 3. Discharge 
decreased upon visits with more dryness observed after 4 weeks of 
treatment. Signs of healing and tympanic perforation closure apparently 
occur about 1 month from initial treatment in 32 patients.
20% of patients who do not respond to medical treatment for 6 weeks 
referred for surgical treatment. Four women and six men of 50-70 years 
age group were not responded to medical treatments. 4 (85%) patients 
with diabetes mellitus were from those who not respond to treatment.
Adverse drug reactions were mild including gastric irritation, nausea, 
or vomiting mainly experienced in elderly patients after 4 weeks of 
continuous medical treatment; they were asked to stop treatment for 
1 week and antacid prescribed to them and then start again for the 
rest of the period. Otherwise, levofloxacin was well tolerated by other 
patients during the treatment period of 6 weeks. Culture sensitivity 
tests results were P. aeruginosa and Klebsiella species in most of 
patients’ discharge materials.
DISCUSSION
CSOM is one of the life-disabling diseases that followed with serious 
complications. Treatment may be medical or surgical. Since CSOM is 
inflammatory disease with bacterial inhabitant, treatment focused on 
antibiotics with bactericidal activity to eradicate pathogenic bacteria 
and allow dryness of discharge to promote healing. Selection of 
appropriate antibiotic is important putting in consideration efficiency, 
safety, and compliance of patients.
The current study focused on aural toilet and medical treatment 
using one of the respiratory fluoroquinolones levofloxacin as an 
effective systemic treatment according to many studies than aural 
toilet alone or with different types of antibiotics used systemically or 
topically [15-17]. Of 50 patients included in the current study, 80% 
of them successfully treated with levofloxacin for 6-week treatment 
with great number within 4 weeks of treatment. The result of this 
study shows that levofloxacin  is a proper choice and  effective 
especially  against P. aeruginosa and Klebsiella which detected in 
culture sensitivity test. Species of microorganism detected in our 
study agrees with Rath etal.,2016 [18] and Renukanada etal., [19]. 
A previous study by Hwang et al., 2015 [20] which compared 
the efficiency of vancomycin and arbekacin found no significant 
difference in efficiency but with more adverse effect with vancomycin 
in methicillin-resistant S. aureus (MRSA)-associated CSOM. While, in 
the current study, the main species detected were P. aeruginosa and 
Klebsiella not MRSA. Levofloxacin allows single dosing regimen, which 
is much easier for patients especially for a long period with lower 
mistake chances as levofloxacin has long clearance half-life [20]. 
Levofloxacin 500 mg shows mild adverse reaction during the study 
period, which occurs in elderly patients only. Elderly patients usually 
have impairment in elimination process that may cause accumulation 
of drug leading to adverse reactions; this could be an explanation 
although we did not confirm by creatinine clearance test. Failure in 
medical treatment in this study was about 20% (10) patients, four of 
them had diabetes which means most of the diabetic patients were 
recorded. This finding may be due to the impact of diabetes mellitus 
on microcirculation, which decreases drug concentration in the 
infected area that dedicates use of other treatment modality rather 
than single antibiotic treatment.
Most of the patients included in the study were rural patient (80%) 
with low socioeconomic status (Table 2) and that goes with other 
studies which declare the impact of lower socioeconomic status on the 
prevalence of CSOM [21-24].
CONCLUSION
Levofloxacin is safe and effective drug for treatment of CSOM and 
promising treatment for CSOM in combination with aural toilet. The 
main species of microorganism detected were P. aeruginosa and 
Klebsiella.
Table 1: Number of patients according to age group





Sample size, 50 patients
Table 3: Percentage of patients with complete discharge dryness 
and healing during follow‑up visits
Time for initial 
treatment
Number of patients 
with complete dryness
Percentages
2 weeks 3 patients 7.5
4 weeks 32 patients 80
6 weeks 5 patients 12.5
Table 2: Clinical criteria of patients included in this study
Criteria Percentage of patients
Sex 65% males - 35% females
Conductive hearing loss 100%
Diabetes mellitus 10%




Patients origin 80% rural 20% urban
Previous antibiotic treatment 100%
Data expressed as percentages
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